
Relativity Holdings Inc.
76
Recent developments include the company entering into a term sheet for a potential equity purchase facility of up to US$150 million to raise capital over three years, subject to conditions and approvals. There is limited recent news coverage otherwise.
- On July 24, 2026, the company entered into a term sheet with Chardan for a standing equity facility of up to US$150 million to raise financing at market pricing over a three-year period, subject to definitive documentation, registration statement effectiveness, and regulatory approvals [S1][S2].
- The company has not reported any material cybersecurity incidents and maintains cybersecurity risk management processes [S1].
- There is limited recent news coverage, with the most notable article from August 19, 2021, discussing insider ownership of shares [N1].
Instinct Bio Technical Company Holdings Inc. (BIOT) is a Cayman Islands exempted company incorporated in May 2025 to complete a business combination. The combined business includes Instinct Bio Technical Company Inc., Instinct Brothers Co., Ltd, and subsidiaries. The company’s principal executive office is in Tokyo, Japan. BIOT operates through its subsidiaries and holds property, plants, and equipment through these entities. It is listed on the Nasdaq Capital Market as a foreign private issuer and follows Cayman Islands corporate governance practices. The company has established compliance policies including a Code of Ethics, insider trading policies, and cybersecurity risk management. It has entered into a term sheet for a potential equity purchase facility to raise capital [S1][S2].
Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice. Instinct Bio Technical Company Holdings Inc. is a Cayman Islands incorporated foreign private issuer with principal operations in Japan. The company was formed through a business combination consolidating Instinct Bio Technical Company Inc., Instinct Brothers Co., Ltd and subsidiaries. It operates through BIOT and its subsidiaries, holding property, plants, and equipment accordingly. The company has adopted governance and compliance policies consistent with its listing on Nasdaq Capital Market. Recently, it entered into a term sheet for a potential equity purchase facility of up to US$150 million [S1][S2].
The company has completed a business combination consolidating multiple entities, potentially creating operational synergies. It has access to a potential equity purchase facility of up to US$150 million, which could provide financial flexibility. The adoption of governance and compliance policies consistent with Nasdaq listing standards may support investor confidence. The company’s operations in Japan and Cayman Islands incorporation may offer strategic advantages in respective markets [S1][S2].
The company is a foreign private issuer with governance practices differing from U.S. standards, which may afford shareholders less protection. There is limited public information on the company’s business model, financial performance, and competitive positioning. The equity purchase facility is subject to conditions and approvals, with no assurance of execution. The company has no current plans to pay cash dividends, which may limit returns to shareholders [S1].
The company’s moat is not explicitly detailed in the available disclosures. It operates through a combination of entities with property, plants, and equipment, suggesting some operational infrastructure. The company’s governance and compliance frameworks align with Nasdaq listing requirements, which may support operational stability. However, specific competitive advantages, proprietary technologies, or market positioning are not described in the provided information [S1].
• Governance and Regulatory Risks: As a Cayman Islands incorporated foreign private issuer, the company follows home country governance practices that differ from U.S. standards, potentially offering less shareholder protection.
• Capital Raising Uncertainty: The proposed equity purchase facility of up to US$150 million is subject to definitive documentation, regulatory approvals, and market conditions, with no guarantee of completion.
• Limited Public Financial Disclosure: Financial details are primarily incorporated by reference, limiting transparency into the company’s financial health and operational results.
• No Dividend Policy: The company has no current plans to pay cash dividends, which may affect shareholder returns.
Business trends: The company is consolidating operations post-business combination and exploring capital raising options through an equity purchase facility.
Execution milestones: Completion of definitive documentation and regulatory approvals for the equity purchase facility; ongoing compliance with Nasdaq listing and governance standards.
Key risks: Governance differences as a foreign private issuer, uncertainty in capital raising execution, limited public financial transparency, and absence of dividend payments.
High visibility
Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).
- The legal name of the company is Instinct Bio Technical Company Holdings Inc., incorporated in the Cayman Islands on May 22, 2025, for the purpose of completing a business combination [S1].
- Following the business combination, the business of Instinct Bio Technical Company Inc., Instinct Brothers Co., Ltd and its subsidiaries became the business of Instinct Bio Technical Company Holdings Inc. [S1].
- The company’s principal executive office is located in Tokyo, Japan [S1].
- The company operates through BIOT and its subsidiaries as a combined entity after the business combination [S1].
- The company’s property, plants, and equipment are held through BIOT and its subsidiaries [S1].
- The company is a foreign private issuer listed on Nasdaq Capital Market and follows Cayman Islands corporate governance practices, which differ from U.S. standards [S1].
- The company has adopted a Code of Business Conduct and Ethics, insider trading policies, and an executive officer compensation clawback policy [S1].
- The company has implemented cybersecurity risk management processes and has not experienced any material cybersecurity incidents as of the latest report [S1].
- The company entered into a term sheet with Chardan for a standing equity facility of up to US$150 million to raise financing at market pricing over a three-year period, subject to conditions and approvals [S1,S2].
- Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice.
- There is limited recent news coverage, with one notable article discussing insider ownership of shares dated August 19, 2021 [N1].
Generated 2026-07-30
- S1 | 2026-07-28 | 20-F
- S2 | 2026-07-28 | 6-K
- N1 | 2021-08-19 | www.nasdaq.com | What Percentage Of Biotech Acquisition Company (NASDAQ:BIOT) Shares Do Insiders Own? | https://www.nasdaq.com/articles/what-percentage-of-biotech-acquisition-company-nasdaq:biot-shares-do-insiders-own-2021-08
This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Generated by Valye SEC Pipeline Engine
.gif)


